Aeglea Biotherapeutics’ (NASDAQ:AGLE) lock-up period will expire on Tuesday, October 4th. Aeglea Biotherapeutics had issued 5,000,000 shares in its public offering on April 7th. The total size of the offering was $50,000,000 based on an initial share price of $10.00. After the expiration of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Separately, Zacks Investment Research cut Aeglea Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 11th.
Aeglea Biotherapeutics (NASDAQ:AGLE) opened at 6.41 on Monday. The company has a 50 day moving average of $6.38 and a 200 day moving average of $6.58. The company’s market capitalization is $85.96 million. Aeglea Biotherapeutics has a 52-week low of $3.89 and a 52-week high of $12.75.
Aeglea Biotherapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.03. On average, equities research analysts forecast that Aeglea Biotherapeutics will post ($4.77) earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Ghost Tree Capital LLC acquired a new stake in Aeglea Biotherapeutics during the second quarter valued at approximately $243,000. Perceptive Advisors LLC acquired a new stake in Aeglea Biotherapeutics during the second quarter valued at approximately $515,000. Finally, VHCP Management II LLC acquired a new stake in Aeglea Biotherapeutics during the second quarter valued at approximately $1,527,000. 40.71% of the stock is currently owned by institutional investors.
Aeglea Biotherapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
Receive News & Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.